



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE USA, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.

Press release

Cantargia AB
556791-6019
17 March 2015

First day of trading in Cantargia shares and option rights on Nasdaq First North Stockholm

Today, 17 March 2015, trading begins in Cantargia AB's ("Cantargia") shares and option rights of series TO 3 and TO 4 on Nasdaq First North Stockholm.

Cantargia AB – developing a new type of cancer treatment

Cantargia is developing an antibody-based cancer treatment which attacks mature cancer cells as well as cancer stem cells – the root of the disease. The company has selected and applied for a patent for a product candidate, targeted at IL1RAP, which has a specific and strong bind to leukaemia stem cells and mature cancer cells. In preclinical studies the antibody has been shown to have two potential mechanisms of action which complement each other: it helps the immune system's killer cells to identify and attack the source of the disease, and it blocks the signals from the target molecule, preventing the cancer cells from spreading. Studies will be carried out to determine safe doses for future treatment of patients. In 2015 Cantargia will carry out further preclinical studies, primarily in solid tumours. The results of these studies will provide guidance for which indications should be the subject of future clinical studies.

In January/February 2015 Cantargia successfully completed an issue of units consisting of shares and option rights, initially raising around SEK 44.1 million before issue costs. If all option rights are exercised the company would raise a further estimated SEK 55.1 million at a later stage through option rights.

Trading on Nasdaq First North Stockholm

Trading in the company's shares and option rights begins today. The shares trade under the ticker CANTA and have the ISIN code: SE0006371126. Option rights of series TO3 trade under the ticker CANTA TO 3 with the ISIN code: SE0006731808 and option rights of series TO 4 trade under the ticker CANTA TO 4 with the ISIN code: SE0006731816.

Summary of terms and conditions for option rights

Holders of option rights of series TO 3 have the right, for each option right held, to subscribe for one new share of the company at a price of SEK 7.60. Option rights of series TO 3 for subscription of shares will be exercisable during the period 23 March – 13 April 2016. If all option rights of series TO 3 are exercised Cantargia would raise around SEK 33.1 million before issue costs.

Holders of option rights of series TO 4 have the right, for each option right held, to subscribe for one new share of the company at a price of SEK 7.60. Option rights of series TO 4 for subscription of shares will be exercisable during the period 27 September – 18 October 2016. If all option rights of series TO 4 are exercised Cantargia would raise around SEK 22 million before issue costs.

Upcoming investor events

In the next few weeks Cantargia's CEO, Göran Forsberg, will be participating at a number of investor meetings, where he will present the company.

- 17 March 2015, 18.30-19.00, Investor Forum, Redeye AB, Mäster Samuelsgatan 42, Stockholm.
- 18 March 2015, 15.50-16.20, InvestorDagen, Radisson Blu Scandinavia Hotel, Amager Boulevard 70, Copenhagen.
- 26 March 2015, 14.15-14.45, Sedermeradagen, Medicon Village, Scheelevägen 2, Lund.

Certified Adviser

Sedermersa Fondkommission is the company's Certified Adviser and financial adviser for the IPO.

For further information, please contact

Göran Forsberg, CEO

Telephone: +46 (0)46-275 62 60

E-mail: goran.forsberg@cantargia.com

Cantargia AB (reg.no. 556791-6019) is a biotech company that is developing an antibody-based cancer treatment, which attacks cancer stem cells as well as mature cancer cells. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, IL1RAP, in cancer stem cells in patients with leukaemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate for future studies in humans. Preclinical trials with Cantargia's antibodies have shown a potent antileukaemic effect. Parallel studies have shown an even higher expression of IL1RAP in certain solid tumours. In 2015 Cantargia will be carrying out the studies required for authorisation of clinical trials.